Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31300446 | 1.00 | NQO2 (0.54) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL31078221 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL6511791 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL5609972 | 0.81 | NQO2 (0.63) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL5513121 | 0.81 | CA2 (0.57) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL497025 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL13911250 | 0.80 | NQO2 (0.57) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL13389442 | 0.77 | NQO2 (0.50) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL13900920 | 0.77 | NQO2 (0.54) | NQO2CA2MTNR1ATDP1CYP1A2 | |
| SCHEMBL16313458 | 0.77 | NQO2 (0.50) | NQO2CA2MTNR1ATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022149617-A1 | COMPOUND LIBRARY | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-9365567-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999031092-A1 | BENZAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999021869-A1 | ERYTHROMYCIN A, 11,12-CARBAMATE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
| CN-1196731-A | Di-glycosylated 1, 2-diols as mimetics of sialyl-lewis X and sialyl-lewis A | NOVARTIS AG (CH) | 1998-10-21 | — | — | CN | disclosed |
| EP-0836610-A1 | DIGLYCOSYLATED 1,2-DIOLS AS MIMETICS OF SIALYL-LEWIS X AND SIALYL-LEWIS A | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| EP-0604184-B1 | Inhibitors of HIV protease useful for the treatment of aids | LILLY CO ELI (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1997001569-A1 | DIGLYCOSYLATED 1,2-DIOLS AS MIMETICS OF SIALYL-LEWIS X AND SIALYL-LEWIS A | NOVARTIS AG (CH) | 1997-01-16 | — | — | WO | disclosed |
| US-5554653-A | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0652009-A1 | Identification and use of protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604184-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | NQO2 575/4885CA2 4015/4885MTNR1A 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.